MoonLake Immunotherapeutics Prices Upsized $200M Offering at $20/Share
MLTX has more than doubled off its 52-week low of $5.95.
Summary
MoonLake Immunotherapeutics priced an upsized public offering, raising $200 million by selling 9 million Class A shares at $20 each. This capital raise follows the company's announcement of highly positive Week 52 Phase 3 clinical trial results for sonelokimab on June 22nd, and a preliminary offering launched on the same day. The $200 million infusion is a material capital raise for the company, providing significant funding to advance sonelokimab towards potential commercialization. The offering was upsized from an initial $150 million, suggesting robust investor demand, although the pricing at $20 per share is below the current market price, causing dilution for existing shareholders. The company has a Q3 2026 BLA submission target for sonelokimab.
At the time of this announcement, MLTX was trading at $21.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $5.95 to $62.75. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.